Price is based on future sales into Asia. Once SRMA is out of the way, we will probably see more contracts being signed. This will kick share price further along.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025